How to Help Your Patients Find Hyrimoz in Stock: A Provider's Guide

When a patient calls your office saying they can't get their Hyrimoz filled, the clock is ticking. Interruptions in adalimumab therapy can cause disease flares, jeopardize remission, and create significant patient anxiety. This guide gives you a practical, step-by-step protocol to help your patients navigate the current specialty pharmacy and insurance landscape quickly and effectively.

Step 1: Identify the Root Cause of the Access Problem

Before taking action, determine why the patient can't fill Hyrimoz. The cause shapes the solution. Have your staff ask the patient or the specialty pharmacy:

Is prior authorization missing, expired, or denied?

Has the patient's insurance changed its formulary (Hyrimoz now non-preferred)?

Is the specific formulation (dose/concentration) not in stock at the patient's specialty pharmacy?

Is the patient enrolled with the wrong specialty pharmacy (not in-network for their plan)?

Is the patient experiencing a cost/affordability barrier?

Step 2: Resolve Prior Authorization Issues Fast

Prior authorization (PA) problems are the most common cause of Hyrimoz access delays. Here's how to resolve them quickly:

Use CoverMyMeds: Sandoz supports electronic PA submission via CoverMyMeds for Hyrimoz. This significantly speeds up the process compared to fax-based PA submissions.

Submit a peer-to-peer request: If the PA is denied, call the insurance plan's medical director for a peer-to-peer review. This is particularly effective for patients who have already achieved disease control on adalimumab.

Engage Sandoz One Source: Sandoz's case managers (1-833-497-4669) can assist with PA documentation and appeals. They have experience with specific payer requirements.

Request an expedited PA: For patients at risk of disease flare due to treatment interruption, most payers offer an expedited (urgent) PA review that can be completed within 24–72 hours instead of the standard 14 days.

Step 3: Navigate Formulary Issues

If the patient's insurance has changed its preferred biosimilar:

Identify the new preferred adalimumab biosimilar on the plan and determine whether switching is clinically appropriate

If the patient is stable on Hyrimoz and the switch is low risk, consider prescribing the formulary-preferred interchangeable biosimilar (e.g., Cyltezo for Express Scripts patients)

If there are clinical reasons to maintain Hyrimoz specifically, submit a formulary exception request with supporting clinical documentation

For patients who have failed other biologics, document the treatment history carefully — this strengthens exception requests

Step 4: Help the Patient Find the Right Specialty Pharmacy

Specialty pharmacies with the highest Hyrimoz availability in 2026 include CVS Specialty, Accredo, OptumRx Specialty, and AllianceRx Walgreens Prime. However, in-network status varies by insurance plan. Your office should:

Confirm which specialty pharmacy is in-network for the patient's plan

Send the prescription directly to that specialty pharmacy (not a retail location)

Ask the specialty pharmacy to ship the medication to the patient's home — most patients prefer this and it's standard practice for Hyrimoz

For real-time pharmacy availability data, your staff can use medfinder.com/providers to quickly identify which pharmacies near the patient have Hyrimoz in stock.

Step 5: Address the Formulation Transition if Needed

If a patient was on the Hyrimoz low-concentration (50 mg/mL) formulation being discontinued, transition them to the high-concentration citrate-free (100 mg/mL) version. Key points for the transition:

No dose adjustment is required — the same number of milligrams are delivered

The injection volume is smaller with the high-concentration formulation (0.4 mL vs 0.8 mL for the 40 mg dose)

The high-concentration formulation is citrate-free, which may actually reduce injection site pain for patients who reported discomfort with the low-concentration formulation

Patient education is needed — review injection technique with the new device

Building a Proactive Protocol in Your Practice

The best way to protect your patients from Hyrimoz access gaps is to be proactive rather than reactive. Consider implementing these practice-level protocols:

Track PA expiration dates for all patients on specialty biologics and submit renewals 60+ days in advance

Conduct a formulary review at the start of each year (January 1 is when most plan changes take effect)

Establish a direct relationship with Sandoz One Source for streamlined PA and patient support

Educate patients to contact your office 3–4 weeks before running out, rather than waiting until they're out of medication

For the broader clinical context on the Hyrimoz market, see our Hyrimoz shortage provider briefing.